3-(4-Amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives and their use as precursors for the preparation of radiochemical compounds

The development of 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives with suitable leaving groups enables a one-step radiosynthesis, addressing inefficiencies in existing methods and improving the production of 18F-labeled compounds for diagnostic and therapeutic use.

DE102019112040B4Active Publication Date: 2024-11-14HELMHOLTZ ZENTRUM DRESDEN ROSSENDORF
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
DE102019112040
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-05-08
Publication Date
2024-11-14
Estimated Expiration
2039-05-08

AI Technical Summary

Technical Problem

Existing methods for synthesizing 18F-labeled 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives require multiple steps, leading to inefficiencies and lower yields.

Method used

Development of 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives with specific leaving groups that enable a one-step radiosynthesis process, allowing direct nucleophilic substitution with 18F-fluoride without the need for protective groups.

Benefits of technology

Facilitates the rapid and efficient production of 18F-labeled compounds, enhancing yield and reducing synthesis time, suitable for radiopharmaceuticals targeting monocarboxylate transporters for diagnostic and therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Combination of the general formula (E)-I or (Z)-I wherein Y a hydroxy group or an O - M + -group is where M + a cation is; Z 1 selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X consists of A 1a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain in the formation of an ether group, and X is selected from the group consisting of a methyl group, a halogen, and a hydroxyl group; and Z 2 a remainder that carries a departure group AG, where Z 2 selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -AG a group -A2 -AG is, in which A 2 a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom may be arranged in the hydrocarbon chain in the form of an ether group; and AG is selected from the group consisting of a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic ester, an organotin compound, an iodonium ion, an iodonium salt, an iodonium ylide and a sulfonate.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The invention relates to 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives, their use as precursors for the preparation of radiochemical compounds and a process for the preparation of the radiochemical compounds.

[0002] WO 2013 / 109972 A2 discloses derivatives of compound B shown below, which have a functionalized benzene ring. Examples of such derivatives are compounds C and D, also shown below. The compounds described in WO 2013 / 109972 A2 are said to be monocarboxylate transporter inhibitors. The described compounds are therefore said to be suitable as potential anticancer agents. WO 2013 / 109972 A2 describes the use of these compounds for the treatment of cancer and autoimmune diseases, as well as for therapeutic modification of brain functions.

[0003] Monocarboxylate transporters (MCTs) are plasma membrane proteins that catalyze the transport of monocarboxylates such as lactates, pyruvates, and ketone bodies across the plasma membrane. They are involved in cellular metabolism. To date, 14 isoforms are known, including MCT1 and MCT4. In the brain, MCT1 is expressed by endothelial cells, ependymal cells, and astrocytes, while MCT4 is expressed only by astrocytes. MCT1 is known to be highly expressed in non-hypoxic areas of human colon, brain, breast, lung, and other tumors. It is therefore possible that compounds that inhibit or modulate MCT1 expression could be used clinically.

[0004] It is also known that the compound FACH shown below exhibits high inhibitory activity against certain MCTs. The IC 50 against MCT1 11 nM, the IC 50 against MCT4 6.4 nM.

[0005] The radiosynthesis of [ 18 F]FACH is proposed to be prepared via a two-step synthesis using a precursor P-SdT, which contains a tert-butyl protecting group to protect the OH functionality.

[0006] It is therefore desirable to find precursors that allow a one-step synthesis of compounds such as [ 18 F]FACH and other 18F-labeled 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives. In this way, compounds such as [ 18 F]FACH and other 18F-labeled 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives can be obtained faster and in higher yields.

[0007] Sadeghzadeh, Masoud, et al., in “Development and radiosynthesis of the first 18F-labeled inhibitor of monocarboxylate transporters (MCTs)” (Journal of Labelled Compounds and Radiopharmaceuticals (2019)), disclose a method for the radiosynthesis of [ 18 WO 2015 / 004029A1 describes a method for 18 F-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups is known. Ligands for imaging are known from US 2011 / 0217234 A1.

[0008] The object of the invention is to eliminate the disadvantages of the prior art. In particular, 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives are to be provided that are suitable as precursors for the one-step synthesis of radiolabeled compounds. Furthermore, the use of the 3-(4-amino-2-methoxyphenyl)-2-cyanoacrylic acid derivatives as precursors for the synthesis of the radiolabeled compounds and a process for preparing the radiolabeled compounds are to be provided.

[0009] This object is achieved by the features of claims 1, 9, and 12. Advantageous embodiments of the inventions emerge from the features of the subclaims.

[0010] According to the invention, a compound of general formula (E)-I or (Z)-I is provided, wherein Y is a hydroxy group or an O - M + -group, where M + is a cation; Z 1is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1 is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2is a residue carrying a leaving group AG, where Z 2 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -AG a group -A 2 -AG is, in which A 2 is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group; and AG is selected from the group consisting of a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, an organotin compound, an iodonium ion, an iodonium salt, an iodonium ylide, and a sulfonate.

[0011] The compounds of formula (E)-I and the compounds of formula (Z)-I are hereinafter referred to collectively as compounds of formula I. The compounds of formula I according to the invention include both their (E) and (Z) isomers. They also include mixtures of the (E) and (Z) isomers.

[0012] It may be provided that groups Z 1 and Z 2 , except for the exit group AG, are similar to each other. However, they can also be different from each other, except for the exit group AG.

[0013] In connection with the rest Z 2the term “unsubstituted” means that the residue Z 2 has no further substituents apart from the leaving group AG. In addition, in connection with the residue Z 2 the term “substituted” means that the residue Z 2 in addition to the leaving group AG, has one or more further substituents.

[0014] It can be provided that at least one of the hydrogen atoms of the residue Z 1 Deuterium (D) or tritium (T). It can be provided that at least one of the hydrogen atoms of the residue Z 2 which do not belong to the leaving group AG, is deuterium (D) or tritium (T).

[0015] A substituted methylene group is understood to be a methylene group in which one or two hydrogen atoms are each replaced by a branched or unbranched C1- to C6-alkyl group. The hydrocarbon chain may contain no heteroatoms. Alternatively, however, at least one oxygen atom may be arranged in the hydrocarbon chain to form an ether group. The methylene groups of the hydrocarbon chain may be independently substituted or unsubstituted. Thus, one or more of the methylene groups may be unsubstituted, while other methylene groups are substituted. If several substituted methylene groups are present, the methyl groups may be substituted in the same way or in different ways.

[0016] A 1 and A 2 can be independently -(CH2) m -(O) p -(CH2)n - where p is 0 or 1, m is an integer from 0 to 4, n is an integer from 0 to 4, with the proviso that m + n is 1, 2, 3 or 4. If p is 0, then -(CH2) m -(O) p -(CH2) n - a hydrocarbon chain consisting of one to four unsubstituted methylene units. If p is 1, the hydrocarbon chain contains an ether group. The CH2 groups can be unsubstituted or substituted by one or two branched or unbranched C1 to C6 alkyl groups.

[0017] It may be provided that A 1 and A 2 are each independently a hydrocarbon chain with one to four unsubstituted methylene groups which does not contain any oxygen atoms.

[0018] It may be provided that the compound of general formula I according to the invention does not contain fluorine.

[0019] The compounds of general formula I according to the invention have a leaving group AG, which enables the preparation of a radiolabeled compound in a one-step synthesis. The use of a protecting group is not required. For example, no protecting group is required even if Y is a hydroxy group. The leaving group AG enables nucleophilic substitution of a compound of general formula I with [ 18 F]Fluoride at an aliphatic position.

[0020] Compounds of general formula I in which Y is a hydroxy group contain a carboxy group. The carboxy group forms an acid function which is neutral with respect to its charge. In compounds of general formula I in which Y is an O - M + -group, the acid function induced by the C(O)O - M + -unit is formed, present as a salt. M +denotes a cation. The cation can, for example, be an alkali metal ion. A preferred cation is selected from the group consisting of a sodium ion, a potassium ion, and a lithium ion. In a preferred embodiment, Y is a hydroxy group or an O - M + -Group in which M + a sodium ion, a potassium ion or a lithium ion.

[0021] It may be intended that AG is a sulfonate. The term “sulfonate” refers to a R s -SO2-O-group. R s can be, for example, a branched or unbranched substituted or unsubstituted C1-C6 alkyl group, an aryl group or an alkylaryl group. Preferably, R sCH3-, CF3-, or CH3-C6H4-. The sulfonate can, for example, be selected from the group consisting of a toluenesulfonic acid ester group, a methylsulfonic acid ester group, and a trifluoromethylsulfonic acid ester group. A toluenesulfonic acid ester group is understood to be an -OTs group, where Ts is tosyl. A methylsulfonic acid ester group is understood to be an -OMs group, where Ms is mesyl. A trifluoromethylsulfonic acid ester group is understood to be CF3-SO2-O-. Preferably, AG is -OMs or -OTs. Particularly preferred is AG -OMs.

[0022] It may be provided that AG is an organotin compound. This may be an organotin compound. The organotin compound may be, for example, alkyltin, whose alkyl group(s) may be substituted or unsubstituted, with one or more of the alkyl groups optionally containing one or more heteroatoms, or aryltin, whose aryl group(s) may be substituted or unsubstituted, with one or more of the aryl groups optionally containing one or more heteroatoms.

[0023] In one embodiment of the invention, a compound of the general formula (E)-IA and (Z)-IA is provided, in which Z 1 -A 1 -X is and Z 2 -A 2 -AG, where X, Y, A 1 , A 2 and AG have the meanings given in connection with formula (E)-I and (Z)-I.

[0024] In one embodiment of the invention, a compound of the general formula (E)-IA and (Z)-IA is provided, in which X, Y, A 1 and A 2 have the meanings given in connection with formula (E)-I and (Z)-I and AG is a sulfonate or an organotin compound.

[0025] It can be provided that at least one of the hydrogen atoms of the residue A 1 Deuterium (D) or tritium (T). It can be provided that at least one of the hydrogen atoms of the residue X is deuterium (D) or tritium (T). It can be provided that at least one of the hydrogen atoms of the residue A 2 Deuterium (D) or Tritium (T).

[0026] In one embodiment, the invention relates to a compound of general formula (E)-IA or (Z)-IA, in which AG -OMs is; X is a methyl group; Y is a hydroxy group; A 1 -(CH2)2-; and A2 -(CH2)3-.

[0027] Preferred examples of compounds of the general formula (E)-IA or (Z)-IA are given in Table 1 below. Table 1 Verbindung Struktur Name A1 (E)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)phenyl)-acrylsäure; A2 (Z)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)phenyl)-acrylsäure; A3 (E)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)-amino)phenyl)acrylsäure A4 (Z)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)-amino)phenyl)acrylsäure.

[0028] Another preferred example is a mixture of compound A1 and compound A2. Another preferred example is a mixture of compound A3 and compound A4. A particularly preferred compound is compound A1.

[0029] In another embodiment, a compound of general formula (E)-I or (Z)-I is provided in which Z 1 is selected from the group consisting of a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted heteroaryl group; Z 2is a residue carrying a leaving group AG, where Z 2 is selected from the group consisting of a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group and a substituted or unsubstituted aryl group; and Y and AG have the meanings given in connection with formula (E)-I and (Z)-I.

[0030] In one embodiment, a compound of general formula (E)-I or (Z)-I is provided in which Z 1 is selected from the group consisting of allyl, propargyl, phenyl and pyridyl, with phenyl and pyridyl being particularly preferred; Z 2 is a residue carrying a leaving group AG, where Z 2 is selected from the group consisting of allyl, propargyl, phenyl and pyridyl, with phenyl and pyridyl being particularly preferred; and Y and AG have the meanings given in connection with formula (E)-I and (Z)-I.

[0031] In one embodiment, a compound of general formula (E)-I or (Z)-I is provided in which Z 1 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2 is a residue carrying a leaving group AG, where Z 2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, preferably phenyl or pyridyl; Y has the meaning given in connection with formula (E)-I and (Z)-I; and AG is selected from the group consisting of a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, alkyltin, aryltin, an iodonium ion, an iodonium salt, and an iodonium ylide.

[0032] In one embodiment, a compound of general formula (E)-I or (Z)-I is provided in which Z 1 phenyl or pyridyl; Z 2 is a residue carrying a leaving group AG, where Z 2 phenyl or pyridyl; Y has the meaning given in connection with formula (E)-I and (Z)-I; and AG is selected from the group consisting of a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, alkyltin, aryltin, an iodonium ion, an iodonium salt, and an iodonium ylide.

[0033] An example of a boronic acid ester is 2,4,4,5,5-pentamethyl-1,3,2-dioxaborolane. Preferred iodonium ylides are sterically hindered spirocyclic iodonium ylides.

[0034] The term “halogen” refers, unless otherwise specified, to fluorine, chlorine, bromine or iodine.

[0035] The term "alkyl," unless otherwise stated, refers in particular to a saturated aliphatic hydrocarbon group having a branched or unbranched carbon chain of 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and most preferably 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like. The alkyl group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise.

[0036] The term “heteroalkyl”, unless otherwise stated, refers in particular to an alkyl radical as defined herein wherein one, two or three hydrogen atoms are replaced by a substituent independently selected from the group consisting of -OR a , -NR b R c and -S(O) n R d (where n is an integer from 0 to 2), provided that the point of attachment of the heteroalkyl radical is a carbon atom, where R a is hydrogen, acyl, alkyl, cycloalkyl or cycloalkylalkyl; R b and R c are independently hydrogen, acyl, alkyl, cycloalkyl or cycloalkylalkyl; and when n is 0, R d hydrogen, alkyl, cycloalkyl or cycloalkylalkyl, and when n is 1 or 2, R dAlkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino. Representative examples include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2-hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, aminosulfonylpropyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like.

[0037] The term "cycloalkyl," unless otherwise specified, refers specifically to saturated carbocyclic groups consisting of mono- or bicyclic rings. The cycloalkyl group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof, such as cyclohexenyl, cyclopentenyl, and the like.

[0038] The term "alkenyl," unless otherwise stated, refers in particular to an unsaturated aliphatic hydrocarbon group having a branched or unbranched carbon chain of 2 to 12 carbon atoms, preferably 2 to 8 carbon atoms, and most preferably 2 to 6 carbon atoms, which has at least one olefinic double bond and more preferably a single double bond. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, methallyl, 1,1-dimethylallyl, propenyl, butenyl, pentadienyl, hexenyl, octenyl, and the like. An allyl group is preferred. The alkenyl group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise.

[0039] The term "alkynyl," unless otherwise stated, refers in particular to an unsaturated aliphatic hydrocarbon group having a branched or unbranched carbon chain of 2 to 12 carbon atoms, preferably 2 to 8 carbon atoms, and most preferably 2 to 6 carbon atoms, containing at least one olefinic triple bond and more preferably a single triple bond. Examples of alkynyl groups include, but are not limited to, acetylenyl, propargyl, n-but-2-yn-1-yl, and the like. A propargyl group is preferred. The alkynyl group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise.

[0040] The term "alkoxy," unless otherwise specified, refers in particular to a group of the formula -OR, wherein R is an alkyl group as defined herein. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like. The alkoxy group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise.

[0041] Unless otherwise specified, the term "aryl" refers to a cyclic, aromatic hydrocarbon group consisting of a mono-, bi-, or tricyclic aromatic ring system with 5 to 10 ring atoms, preferably 5 or 6 ring atoms. The aryl group may optionally be a substituted aryl group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, adamantyl, naphthalenyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenyl sulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, including partially hydrogenated derivatives thereof. A preferred example is phenyl.The term "substituted aryl group" refers in particular to an aryl group which may optionally be substituted independently by one to four substituents, preferably one or two substituents, selected from alkyl, cycloalkyl, heteroalkyl, hydroxyalkyl, halogen, nitro, cyano, hydroxy, alkoxy, amino, acylamino, monoalkylamino, dialkylamino, haloalkyl, haloalkoxy, urea, amido, alkanesulfonyl, -COR (wherein R is hydrogen, alkyl, phenyl or phenylalkyl), -(CR'R''). n -COOR (wherein n is an integer from 0 to 5, R' and R'' are independently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl) or -(CR'R'') n -CONR a' R b' (wherein n is an integer from 0 to 5, R' and R'' are independently hydrogen or alkyl and R a' and R b'are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl).

[0042] The term "heteroaryl", unless otherwise stated, refers in particular to a monocyclic, bicyclic or tricyclic group having 5 to 12 ring atoms, wherein at least one aromatic ring contains one, two or three ring heteroatoms selected from N, O or S, the remaining ring atoms being C. The heteroryl group may optionally be a substituted heteroaryl group.Beispiele von Heteroaryl-Gruppen umfassen, sind aber nicht beschränkt auf Imidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Isothiazolyl, Oxadiazolyl, Thiadiazolyl, Pyrazinyl, Pyridazinyl, Thiophenyl, Furanyl, Pyranyl, Pyridyl, Pyrrolyl, Pyrazolyl, Pyrimidyl, Chinolinyl, Isochinolinyl, Chinazolinyl, Benzofuranyl, Benzothiophenyl, Benzothiopyranyl, Benzimidazolyl, Benzoxazolyl, Benzooxadiazolyl, Benzothiazolyl, Benzothiadiazolyl, Benzopyranyl, Indolyl, Isoindolyl, Indazolyl, Triazolyl, Triazinyl, Chinoxalinyl, Purinyl, Chinazolinyl, Chinolizinyl, Naphthyridinyl, Pteridinyl, Carbazolyl, Azepinyl, Diazepinyl, Acridinyl und dergleichen. Ein bevorzugtes Bespiel ist Pyridinyl.The term "substituted heteroaryl group" refers in particular to a heteroaryl group which may optionally be substituted independently by one to four substituents, preferably one or two substituents, selected from alkyl, cycloalkyl, heteroalkyl, hydroxyalkyl, halogen, nitro, cyano, hydroxy, alkoxy, amino, acylamino, monoalkylamino, dialkylamino, haloalkyl, haloalkoxy, urea, amido, alkanesulfonyl, -COR (wherein R is hydrogen, alkyl, phenyl or phenylalkyl), -(CR'R''). n -COOR (wherein n is an integer from 0 to 5, R' and R'' are independently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl) or -(CR'R'') n -CONR a' R b' (wherein n is an integer from 0 to 5, R' and R'' are independently hydrogen or alkyl and R a' and R b'are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl).

[0043] The term “acyl”, unless otherwise stated, refers in particular to a group of the formula -C(=O)R, where R is hydrogen or alkyl as defined herein.

[0044] The term “arylalkyl”, unless otherwise stated, refers in particular to a group of the formula -R e R f , where R e is an alkylene group and R fis an aryl group as defined herein. The arylalkyl group may optionally be a substituted arylalkyl group. Examples of arylalkyl groups include, but are not limited to, benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like. The term "alkylene" refers in particular to a saturated aliphatic hydrocarbon group having a branched or unbranched carbon chain containing 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, and the like. The alkylene group may optionally be substituted with one or more substituents, each substituent independently being hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino, unless specifically stated otherwise.

[0045] The term “alkylaryl”, unless otherwise stated, refers in particular to a group of the formula -R g R h , where R g is an aryl group and R h is an alkyl group as defined herein. The alkylaryl group may optionally be a substituted alkylaryl group. Examples of alkylaryl groups include, but are not limited to, o-tolyl, m-tolyl, p-tolyl, o-tert-butylphenyl, m-tert-butylphenyl, p-tert-butylphenyl, and the like.

[0046] The expression “at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group” means that either no oxygen atom is arranged in the hydrocarbon chain or at least one oxygen atom is arranged to form an ether group.

[0047] A process for the preparation of the compounds of general formula (E)-I or (Z)-I is given in Scheme 1. In the compounds of general formula III, IV and V, Z 1 and Z 2 the meanings given in connection with the general formula (E)-I or (Z)-I. The compound of general formula V corresponds to the compound of general formula (E)-I, where Y is a hydroxy group. The process is based on the process described by Gurrapu S, Jonnalagadda SK, Alam MA, Nelson GL, Sneve MG, Drewes LR, et al. In Monocarboxylate transporter 1 inhibitors as potential anticancer agents. ACS Med Chem Lett 2015;6(5):558. The process is suitable for the preparation of both the (E)-isomer and the (Z)-isomer. The COOH group of the compound of general formula V can be converted into a -COO - M + -group.

[0048] In step (a), 3-methoxyaniline (2) is converted into a compound of general formula III by converting the primary amino group into a tertiary amino group by double alkylation. For this purpose, compound 2 (i) can be reacted with Z 1 X 1 , where Z 1 has the meaning given in connection with the general formula (E)-I or (Z)-I and X 1 fluorine, bromine, chlorine or iodine, preferably bromine, and then (ii) with Z 2 X 2 , where Z 2 has the meaning given in connection with the general formula (E)-I or (Z)-I and X 2 Fluorine, bromine, chlorine, or iodine, preferably iodine. The reaction can be carried out in the presence of an inorganic salt such as K2CO3 and in an organic solvent such as acrylonitrile. The reaction can be carried out at temperatures above room temperature, preferably under reflux.

[0049] In step (b), the compound of general formula III is converted into the compound of general formula IV. The conversion can be carried out by means of a Vilsmeier-Haack reaction. For this purpose, the compound of general formula III can be reacted with dimethylformamide (DMF) in the presence of phosphorus oxychloride (POCl3). The conversion can be carried out at temperatures above room temperature, for example, at 80 °C.

[0050] In step (c), the compound of general formula IV is converted into the compound of general formula V. The conversion can be carried out by means of a base-mediated condensation. For this purpose, the compound of general formula IV is reacted with cyanoacetic acid. The conversion can be carried out in the presence of piperidine in an organic solvent such as acrylonitrile. The conversion can be carried out at temperatures above room temperature, preferably under reflux.

[0051] The following Scheme 2 illustrates the preparation of the compound FACH using the procedure explained in connection with Scheme 1.

[0052] Steps (a), (b) and (c) are based on steps (a), (b) and (c) explained in connection with Scheme 1.

[0053] In step (a), 3-methoxyaniline (2) is reacted to give N-(3-fluoropropyl)-3-methoxy-N-propylaniline (3) (i) with Br(CH2)3 and then (ii) with I(CH2)3F. The reaction can be carried out in the presence of an inorganic salt such as K2CO3 and in an organic solvent such as acrylonitrile. The reaction can be carried out at temperatures above room temperature, preferably under reflux.

[0054] In step (b), N-(3-fluoropropyl)-3-methoxy-N-propylaniline (3) is converted to 4-((3-fluoropropyl)(propyl)amino)-2-methoxybenzaldehyde (4). The conversion can be carried out using a Vilsmeier-Haack reaction. For this purpose, N-(3-fluoropropyl)-3-methoxy-N-propylaniline (3) is reacted with dimethylformamide (DMF) in the presence of phosphorus oxychloride (POCl3). The conversion can be carried out at temperatures above room temperature, for example, at 80 °C.

[0055] In step (c), 4-((3-fluoropropyl)(propyl)amino)-2-methoxybenzaldehyde (4) is converted to FACH. The reaction can be carried out by a base-mediated condensation. For this purpose, compound 4 is reacted with cyanoacetic acid. The reaction can be carried out in the presence of piperidine in an organic solvent such as acrylonitrile. The reaction can be carried out at temperatures above room temperature, preferably under reflux.

[0056] According to the invention, the use of a compound of the general formula (E)-I or (Z)-I as a precursor for the preparation of a compound of the general formula (E)-II or (Z)-II is further provided, wherein Y is a hydroxy group or an O - M + -group, where M + is a cation; Z 1 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2 a remainder that [ 18 F]fluoride, where Z 2 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -[ 18F]F a group -A 2 -[ 18 F]F is, where A 2 a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group.

[0057] The compounds of formula (E)-II and compounds of formula (Z)-II are hereinafter referred to collectively as compounds of formula II. The compounds of formula II according to the invention include both their (E) and (Z) isomers. They also include mixtures of the (E) and (Z) isomers.

[0058] The compound of general formula I differs from the compound of general formula II only in that the substituent AG is replaced by [ 18 F]fluorine. All other substituents, ie Y, Z 1 and Z 2 including X, A 1 and A 2are unchanged and in the same position. Details of the substituents, Y, Z 1 and Z 2 and X, A 1 and A 2 can therefore be taken from the information on the compounds of general formula I according to the invention.

[0059] To prepare a compound of general formula (E)-II, a compound of general formula (E)-I is used. To prepare a compound of general formula (Z)-II, a compound of general formula (Z)-I is used.

[0060] Compounds of general formula II are 18F-labeled compounds that can be used as radiopharmaceuticals, for example as radiotracers. In particular, the compounds of general formula II can be used as radiotracers for monocarboxylate transporters. The compounds of general formula II can be used as radiopharmaceuticals, in particular as radiopharmaceuticals for nuclear medicine imaging of monocarboxylate transporters using positron emission tomography (PET). A compound of general formula (II) can be used as a medicament for the diagnosis and treatment of tumors, for example breast, lung, pancreas, kidney, prostate tumors, and gliomas. It can also be used as a medicament for the diagnosis and treatment of diseases or changes in various organs such as the kidneys, liver, pancreas, intestine, lungs, and brain.The compounds of general formula II are compounds that inhibit the expression of MCT, particularly MCT1 and MCT4. They can therefore be used as radiopharmaceuticals for the diagnosis and treatment of diseases associated with the expression of MCT, particularly MCT1 and MCT4.

[0061] The compounds of general formula I according to the invention are thus precursors for the radiosynthesis of radiopharmaceuticals of general formula II, for example, radiopharmaceuticals for nuclear medicine imaging of monocarboxylate transporters using positron emission tomography. The compounds of general formula I according to the invention are precursors that enable the suitability of compounds of general formula II for nuclear medicine imaging to be evaluated preclinically and clinically.

[0062] In one embodiment, the use of a compound of general formula (E)-IA or (Z)-IA as a precursor for the preparation of a compound of general formula (E)-IIA or (Z)-IIA is provided: wherein X, Y, A 1 and A 2 as defined in connection with the general formula (E)-IA or (Z)-IA. To prepare a compound of the general formula (E)-IIA, a compound of the general formula (E)-IA can be used. To prepare a compound of the general formula (Z)-IIA, a compound of the general formula (Z)-IA can be used.

[0063] In a preferred example of a compound of general formula (E)-IIA, X is a methyl group, Y is a hydroxy group, A 1 -(CH2)2- and A 2 -(CH2)3-. This compound may be (E)-2-cyano-3-(4-((3-([ 18 F]fluoropropyl)(propyl)amino)-2-methoxyphenyl)acrylic acid ([ 18 F]FACH).

[0064] To establish the connection [ 18 For example, one of the following compounds can be used as a precursor for F]FACH or its (Z) isoform: (E)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (Z)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (E)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid; or (Z)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid.

[0065] According to the invention, a process for the preparation of a compound of the general formula (E)-II or (Z)-II is further provided, wherein a compound of the general formula (E)-I or (Z)-I is reacted in the presence of a [ 18 F]-fluoride anion and a phase transfer catalyst to form a compound of the general formula (E)-II or (Z)-II.

[0066] The compound of general formula I differs from the compound of general formula II only in that the substituent AG is replaced by [ 18 F]fluorine. All other substituents, ie Y, Z 1 and Z 2 including X, A 1 and A 2 are unchanged and in the same position. Details of the substituents, X, Y, Z 1 , Z 2 , A 1 and A 2can therefore be taken from the information on the compounds of general formula I according to the invention. In the process according to the invention, the substituent AG is selected from the group consisting of a hydroxyl, -NO2, chlorine, bromine, iodine, a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, an organotin compound, an iodonium ion, an iodonium salt, an iodonium ylide and a sulfonate.

[0067] To prepare a compound of general formula (E)-II, a compound of general formula (E)-I is used. To prepare a compound of general formula (Z)-II, a compound of general formula (Z)-I is used.

[0068] In one embodiment of the process according to the invention, a compound of the general formula (E)-IA or (Z)-IA is converted to a compound of the general formula (E)-IIA or (Z)-IIA. A compound of the general formula (E)-IA can be used to prepare a compound of the general formula (E)-IIA. A compound of the general formula (Z)-IA can be used to prepare a compound of the general formula (Z)-IIA.

[0069] The process according to the invention can be a one-step process. The process according to the invention thus enables a one-step radiosynthesis of compounds of the general formula II. The compounds of the general formula II can be radiopharmaceuticals, for example radiotracers. These compounds can be produced much more efficiently and in a considerably shorter synthesis time using the process according to the invention. In addition to the development of a radiopharmaceutical, this allows access to novel medications and makes an important contribution to their evaluation. The process according to the invention is based on the finding that the introduction of the radionuclide fluorine-18 via nucleophilic substitution (S N 2) a leaving group AG at an aliphatic position is possible.

[0070] The process according to the invention enables the preparation of a compound of general formula II from a compound of general formula I without the need to protect the Y radical of the compound of general formula I, i.e., its acid function. The use of protecting groups to protect the acid function of the compound of general formula I is not necessary. The radiofluorination provided for by the process is nevertheless successful. High radiochemical yields can be achieved.

[0071] It can be provided that for the activation and phase transfer of the [18F]fluoride a phase transfer catalyst with a cation with the general formula N + (R 1 R 2 R 3 R 4 ), where R 1 , R 2 , R 3 and R 4 are the same or different from each other and are each unsubstituted or substituted C1-C6 alkyl. Preferably, R1 , R 2 , R 3 and R 4 in each case unsubstituted C1-C6-alkyl, more preferably propyl, butyl, or pentyl, particularly preferably in each case n-butyl. The phase transfer catalyst may comprise an anion selected from the group consisting of bicarbonate, bisulfate, oxalate, phosphate, and toluenesulfonate. Bicarbonate and phosphate are highly preferred. A particularly preferred phase transfer catalyst is tetra-n-butylammonium bicarbonate. A phase transfer catalyst comprising the tetra-n-butylammonium cation is also referred to below as TBA.

[0072] The phase transfer catalyst is used for the activation and phase transfer of the [ 18 F]fluoride anions. In the phase transfer catalyst, the cation with the general formula N + (R 1 R 2 R 3 R 4) and the anion are present in a stoichiometric ratio.

[0073] The phase-transfer catalyst is preferably present in a polar solution, particularly preferably in a solution with water or a water-containing solvent mixture. The solvent mixture can be, for example, water mixed with an alcohol such as ethanol. The alcohol addition serves to stabilize the solution. The phase-transfer catalyst can be provided, for example, as a 0.001 to 0.1 M solution, in particular as a 0.075 M solution.

[0074] The [ 18 F]Fluoride anion can be prepared by known methods. For example, the [ 18 F]Fluoride anion in the cyclotron by irradiation of at least 97% enriched H2 18 O with protons of an energy of 9.6 MeV. The aqueous [ 18[F]Fluoride solution can be fixed on an anion exchange cartridge (QMA) and transferred into a reaction vessel using a phase-transfer catalyst (PTC), such as crown ethers, quaternary ammonium salts, or alkali or alkaline earth salts. The PTC preferably used is a [2,2,2]-cryptand (Kryptofix® or K222), tetra-n-butyl ammonium phosphate, hydroxide, oxalate, toluenesulfonate, or optionally other crown ethers such as 18-crown-6. After azeotropic drying under vacuum, the compound of general formula I is dissolved in an organic solvent and added to the dried reaction mixture. The organic solvent can be a non-protic, polar solvent such as acetonitrile, dimethylformamide (DMF), N,N-dimethylacetamide (DMAA), N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), or mixtures thereof. Acetonitrile is preferably used as the solvent.The organic solvent can alternatively be a protic, polar solvent such as tert-BuOH, tert-amyl alcohol or other alcohols.

[0075] The process according to the invention is preferably carried out under thermal reaction conditions in a closed reaction vessel at elevated temperature. The temperature is preferably between 50 and 150°C, particularly preferably between 80 and 120°C, particularly preferably at 100°C. The process according to the invention is preferably carried out for a period of 1 to 60 minutes, more preferably 5 to 30 minutes, and particularly preferably 10 to 20 minutes.

[0076] The process according to the invention can also be carried out as a microwave-assisted reaction. For this purpose, microwaves with a power of 50 to 150 W, preferably 65 to 85 W, and particularly preferably 75 W, are irradiated into a special, closed reaction vessel.

[0077] The invention will be explained in more detail below using exemplary embodiments, which are not intended to limit the invention, with reference to the drawings. Fig. 1 HPLC chromatograms to demonstrate the product purity of [ 18 F]FACH; and Fig. 2 PET images illustrating the effects of [ 18 FOLD ( Fig. 2a) and SUBJECT ( Fig. 2b).

[0078] Examples 1 to 7 demonstrate the preparation of (E)-2-cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)phenyl)acrylic acid (Compound A1). Compound A1 is a compound of general formula (E)-I, in which AG is -OMs, X is a methyl group, Y + is a hydrogen ion; A 1 -(CH2)2- and A 2-(CH2)3-. Scheme 3 shows the synthetic route used to prepare compound A1. It should be noted that compound K corresponds to the compound P-SdT mentioned in the prior art.

[0079] Example 8 shows the use of compound A1 as a precursor for the preparation of the radiofluorinated compound (E)-2-cyano-3-(4-((3-([ 18 F]fluoro)propyl)(propyl)amino)-2-methoxyphenyl)acrylic acid (compound [ 18 F]FACH) in a one-step synthesis.

[0080] The structures of compounds F to K and A1 shown in Scheme 3 were determined by 1 H-NMR, 13 C-NMR, 19 F NMR and ESI mass spectroscopy confirmed this. Compounds F to K were prepared as described in Scheme 1. Example 13-((3-Methoxyphenyl)(propyl)amino)propan-1-ol (Compound F)

[0081] 1-Bromopropane (28 mmol) and potassium carbonate (50 mmol) were added to a solution of m-anisidine (20 mmol) in 50 mL of acetonitrile, and the reaction mixture was heated under reflux overnight. After the reaction was complete, 100 mL of a 5% aqueous NaHCO3 solution was added, and the reaction mixture was extracted with ethyl acetate (EA) (3 × 50 mL). The organic phase was then dried with anhydrous Mg2SO4, and the solvent was removed using a rotary evaporator. The residue was purified by column chromatography (silica gel, EA / IH = 0.5:9.5 up to 1:9) to afford the monoalkylated aniline (compound E) in 52% yield [(TLC (silica gel, EA / IH, 2:8): R f = 0.65].

[0082] 1-Iodo-3-hydroxypropane (20 mmol) and potassium carbonate (30 mmol) were added to a solution of 3-methoxy-N-propylaniline (E, 11 mmol) in 50 mL of acetonitrile, and the reaction mixture was heated under reflux overnight. After the reaction was complete, 100 mL of a 5% aqueous NaHCO3 solution was added, and the reaction mixture was extracted with ethyl acetate (3 x 50 mL). The organic phase was then dried with anhydrous Mg2SO4, and the solvent was removed on a rotary evaporator. 3-[(3-Methoxyphenyl)(propyl)amino]propan-l-ol (F) was obtained as a yellow oil in 88% yield.

[0083] TLC (silica gel, EA / IH, 2:8): R f = 0.19. 1 H-NMR (400 MHz, chloroform-d) δ 7.15 (t, J = 8.1 Hz, 1H), 6.38 (dd, J = 8.4, 2.4 Hz, 1H), 6.34-6.10 (m, 2H), 3.82 (s, 3H), 3.74 (t, J = 6.0 Hz, 2H), 3.44 (t, J = 7.1 Hz, 2H), 3.34-3.16 (m, 2H), 2.03 (s, 1H), 1.91-1.76 (m, 2H), 1.64 (h, J = 7.4 Hz, 2H), 0.95 (t, 1 = 7.4 Hz, 3H). 13C-NMR (101 MHz, chloroform-d) δ 160.87, 149.59, 129.91, 105.84, 100.60, 99.25, 60.81, 55.12, 53.28, 48.13, 30.15, 20.29, 11.46. Example 23-((3-Methoxyphenyl)(propyl)amino)propyl acetate (Compound G)

[0084] Acetyl chloride (0.8 mL, 16.5 mmol, 1.5 equiv.) and pyridine (1.7 mL, 33 mmol, 3 equiv.) were added to a solution of compound F in 50 mL of dichloromethane (DCM) (2.5 g, 11 mmol, 1 equiv.), and the reaction mixture was stirred overnight at room temperature. After the addition of 50 mL of ice-cold water, the phases were separated, and the organic phase was dried over anhydrous MgSO. The solvent was then removed on a rotary evaporator, yielding compound G as a yellowish oil, which was used in the next reaction step without further purification.

[0085] TLC (silica gel, EA / IH, 2:8): R f = 0.55. 1H NMR (400 MHz, chloroform-d) δ 7.14 (t, J = 8.1 Hz, 1H), 6.46-6.07 (m, 3H), 4.14 (t, J = 6.3 Hz, 2H), 3.81 (s, 3H), 3.39 (t, J = 7.3 Hz, 2H), 3.24 (t, J = 7.7 Hz, 2H), 2.10 (s, 3H), 1.95 (t, J = 7.1 Hz, 2H), 1.63 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13 C-NMR (101 MHz, chloroform-d) δ 171.08, 160.91, 149.32, 129.92, 105.33, 100.30, 98.83, 62.38, 55.10, 53.13, 47.72, 26.55, 20.97, 20.43, 11.44. Example 33-((4-Formyl-3-methoxyphenyl)(propyl)amino)propyl acetate (Compound H)

[0086] POCl3 (11 mmol) was added dropwise to a solution of compound G (10 mmol) in 60 mL of dimethylformamide at 0 °C, and the reaction mixture was heated under reflux (80 °C) for 2 to 4 hours. Saturated aqueous Na2CO3 solution was then added to the solution, the solid was filtered off, and the mixture was washed with n-hexane. Compound H was obtained quantitatively as a yellow oil.

[0087] TLC (silica gel, EA / IH, 2:8): R f = 0.11. 1H-NMR (400 MHz, chloroform-d) δ 10.19 (s, 1H), 7.76 (d, J = 8.9 Hz, 1H), 6.39 (dd, J = 8.9, 2.3 Hz, 1H), 6.29 (s, 1H), 4.16 (t, J = 6.2 Hz, 2H), 3.93 (s, 3H), 3.57-3.42 (m, 2H), 3.42-3.25 (m, 2H), 2.10 (s, 3H), 2.01 (m, 2H), 1.71 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). Example 44-((3-Hydroxypropyl)(propyl)amino)-2-methoxybenzaldehyde (Compound I)

[0088] A solution of K2CO3 (7 g, 50 mmol, 5 equiv.) in 70 mL of H2O was added to a solution of compound H (2.5 g, 10 mmol, 1 equiv.) in 75 mL of methanol, and the reaction mixture was stirred at room temperature for 30 minutes. Subsequently, 50 mL of a saturated aqueous NaCl solution and 100 mL of DCM were added. The phases were separated, and the organic phase was dried with anhydrous Mg2SO4. After removal of the solvent on a rotary evaporator, compound I was obtained as a yellowish oil, which was used for the next reaction step without further purification.

[0089] TLC (silica gel, EA / IH, 1:1): R f = 0.15. 1 H-NMR (400 MHz, chloroform-d) δ 10.16 (s, 1H), 7.73 (d, J = 8.9 Hz, 1H), 6.38 (d, J = 9.0 Hz, 1H), 6.28 (s, 1H), 3.91 (s, 3H), 3.76 (t, J = 5.8 Hz, 2H), 3.57 (t, J = 7.3 Hz, 2H), 3.36 (dd, J = 8.6, 6.9 Hz, 2H), 1.97-1.84 (m, 2H), 1.70 (h, J = 7.5 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H). Example 5-tert-butyl-(E)-2-cyano-3-(4-((3-hydroxypropyl)(propyl)amino)-2-methoxyphenyl)acrylate (Compound J)

[0090] Tert-butyl cyanoacetate (15 mmol) and piperidine (5 mmol) were added to a solution of compound I (5 mmol) in 20 mL of acetonitrile, and the reaction mixture was heated under reflux (80 °C) overnight. After complete conversion, the solution was poured into a mixture of 3M HCl (10 mL) in ice and stirred for 10 to 15 minutes. The almost quantitatively formed yellow compound J was then separated using a Buchner funnel.

[0091] TLC (silica gel, EA / IH, 1:1): Rf = 0,18. 1 HNMR (300 MHz, Chloroform-d) δ 8,56 (s, 1H), 8,35 (d, J = 9,2 Hz, 1H), 6,38 (dd, J = 9,1, 2,4 Hz, 1H), 6,20 (s, 1H), 3,85 (s, 3H), 3,73 (t, J = 5,8 Hz, 2H), 3,55 (dd, J= 8,1, 6,4 Hz, 2H), 3,38-3,28 (m, 2H), 1,92-1,84 (m, 2H), 1,67 (dt, J= 9,4, 7,4 Hz, 2H), 1,57 (s, 9H), 0,95 (t, J= 7,4 Hz, 3H). 13 C-NMR (101 MHz, Chloroform-d) δ 165,50, 162,26, 154,25, 148,09, 131,17, 118,57, 109,22, 105,34, 93,05, 91,01, 59,70, 55,43, 52,84, 52,57, 47,79, 30,13, 20,62, 14,18, 11,35. HRFT-MS (ESI+): m / z = 375,2340 (berechnet 375,2278 für C 21 H 31 N2O4 + [M+H] + ). Beispiel 6tert-Butyl-(E)-2-cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)-amino)phenyl)acrylate (Verbindung K)

[0092] Methanesulfonyl chloride (30 µL, 0.4 mmol, 1.2 equiv.) and Et3N (130 µL, 0.9 mmol, 3 equiv.) were added to a solution of compound J (100 mg, 0.3 mmol, 1 equiv.) in 5 mL of DCM, and the reaction mixture was stirred at room temperature for 30 minutes. Subsequently, 10 mL of a saturated aqueous NaHCO3 solution was added, the aqueous phase was extracted with DCM (2 × 10 mL), and the combined organic phases were washed with aqueous NaCl solution (10 mL) and dried over anhydrous MgSO4. Compound K was obtained as a yellowish solid by removal of the solvent on a rotary evaporator and used in the next synthesis step without further purification.

[0093] TLC (silica gel, EA / IH, 1:1): R f = 0.22. 1H-NMR (400 MHz, Chloroform-d) δ 8,57 (t, J = 0,5 Hz, 1H), 8,36 (dd, J = 9,2, 0,5 Hz, 1H), 6,32 (dd, J = 9,2, 2,4 Hz, 1H), 6,07 (d, J = 2,5 Hz, 1H), 4,30 (t, J = 5,8 Hz, 2H), 3,85 (s, 3H), 3,64-3,48 (m, 2H), 3,42 - 3,26 (m, 2H), 3,03 (s, 3H), 2,15- 2,01 (m, 2H), 1,67 (q, J = 7,6 Hz, 2H), 1,55 (s, 9H), 0,96 (t, J = 7,4 Hz, 3H). 13 C-NMR (101 MHz, Chloroform-d) δ 163,63, 161,89, 153,25, 147,23, 131,10, 118,40, 109,67, 105,03, 94,59, 93,15, 82,15, 67,35, 55,46, 52,98, 47,22, 37,45, 28,10, 27,20, 20,60, 11,35. HRFT-MS (ESI+): m / z = 453,2134 (berechnet 453,2054 für C 22 H 33 N2O6S + [M+H] + ). Beispiel 7(E)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)phenyl)acrylsäure (Verbindung A1)

[0094] Trifluoroacetic acid (200 µL) was added to a solution of K (20 mg, 0.044 mmol) in 200 µL of DCM, and the reaction mixture was stirred at room temperature for 2 hours. After removal of the solvent on a rotary evaporator, the product, compound A1 (21 mg, 0.044 mmol), was obtained as a yellow solid and used for radiofluorination without further purification. Example 8(E)-2-Cyano-3-(4-((3-([ 18 F]fluoro)propyl)(propyl)amino)-2-methoxyphenyl)acrylic acid (compound [ 18 F]FACH)

[0095] Connection [ 18 F]FACH was prepared in a one-step radiosynthesis using the synthetic route shown in Scheme 4.

[0096] Strapless [ 18 F]Fluoride in 100 to 400 µl of target water was added to a solution of 50 to 150 µl of tetra-n-butylammonium hydrogen carbonate solution (TBAHCO3, 0.075 M) in 1 ml of acetonitrile. Subsequently, the aqueous [ 18F]fluoride was dried by azeotropic distillation under vacuum and nitrogen flow for 7 to 12 minutes. A laboratory microwave oven (75 W, 50-60 °C, power cycling mode) was used. During the drying procedure, acetonitrile was added again (2 × 1.0 ml), and the resulting dry [ 18 F]TBAF was dissolved in 300 to 500 µl of acetonitrile. To this solution, 0.5 to 2.0 mg of precursor Al (Scheme 4), dissolved in 100 to 250 µl of acetonitrile, was added and the 18 F-labeling was performed at 100 °C for 10 to 20 minutes. The radiochemical yields for this step, determined by radio-HPLC, were between 40 and 60%. The isolation of the radiotracer [ 18F]FACH was performed by semipreparative HPLC (Reprosil-Pur C18-AQ or Reprosil-Gold; 250 x 10 mm) using 46% acetonitrile / 54% 20 mM aqueous ammonium formate pH 4 as eluent at a flow rate of 3.5 ml / min. The collected product fraction was finally purified by solid-phase extraction, and the radiotracer was formulated in 0.9% NaCl solution with 10% ethanol. With initial activities of approximately 2 GBq, approximately 300 MBq [ 18 F]FACH can be obtained.

[0097] The identity verification of the 18 F-labeled main product [ 18 F]FACH was isolated by HPLC (radio- and UV detection) by co-injection of the reference compound (E)-2-cyano-3-(4-((3-(fluoro)propyl)(propyl)amino)-2-methoxyphenyl)acrylic acid (FACH) ( Fig. 1). Example 9Demonstration of the inhibitory effect of the compound FACH on MCT1 and MCT4

[0098] In Table 2 below, IC 50-values ​​for the reference compound (FACH) are shown. The IC 50 -values ​​were carried out to further demonstrate that the compound prepared in Example 8 [ 18 F]FACH can be obtained by the process according to the invention in a one-step synthesis. Table 2 Verbindung MCT1 IC 50 [nM] MCT4 IC 50 [nM] FACH 11 6,4

[0099] The IC 50 Values ​​were determined as described in Gurrapu, op. cit.

[0100] Fig. Figure 2a shows a PET image taken with [ 18 F]FACH in a CD-1 mouse. Fig. Figure 2b shows PET images of inhibition experiments performed with α-cyano-4-hydroxycinnamate (CHC) and FACH. It can be seen that the inhibitory effect of FACH exceeds that of CHC. Fig.The PET images shown in Figure 2 are summed images over 60 minutes. The term “SUV” refers to the standardized uptake value, and the term “Baseline” refers to the baseline.

Claims

[1] Compound of the general formula (E)-I or (Z)-Iwherein Y is a hydroxy group or an O - M + -group, where M + is a cation; Z 1 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2 is a residue carrying a leaving group AG, where Z 2 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -AG a group -A2 -AG is, in which A 2 is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group; and AG is selected from the group consisting of a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, an organotin compound, an iodonium ion, an iodonium salt, an iodonium ylide, and a sulfonate. [2] A compound according to claim 1, characterized by that the compound is a compound of the general formula (E)-IA or (Z)-IA, wherein AG is a sulfonate or an organotin compound; X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; Y is a hydroxy group or an O - M + -group, where M + is a cation; and A 1 and A 2 are each independently a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group. [3] A compound according to any one of the preceding claims, characterized by that the sulfonate is selected from the group consisting of a toluenesulfonic acid ester group, a methylsulfonic acid ester group and a trifluoromethylsulfonic acid ester group. [4] A compound according to any one of the preceding claims, characterized by that AG is a methylsulfonic acid ester group. [5] A compound according to any one of the preceding claims, characterized by that M + is an alkali metal ion. [6] Connection according to claim 5, characterized bythat the alkali metal ion is selected from the group consisting of a sodium ion, a potassium ion and a lithium ion. [7] A compound according to any one of claims 2 to 6, characterized by that AG is a methylsulfonic acid ester group; X is a methyl group; Y is a hydroxy group; A 1 -(CH2)2-; and A 2 -(CH2)3-. [8] A compound according to any one of the preceding claims, characterized by that it is one of the following compounds: (E)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (Z)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (E)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid; (Z)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid. [9] Use of a compound according to any one of claims 1 to 8 as a precursor for the preparation of a compound of general formula (E)-II or (Z)-IIwherein Y is a hydroxy group or an O - M + -group, where M + is a cation; Z 1 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2 a remainder that [ 18 F]fluoride, where Z 2 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -[ 18F]F a group -A 2 -[ 18 F]F is, where A 2 a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group. [10] Use according to claim 9, characterized by that a compound of the general formula (E)-IA or (Z)-IA is used to prepare a compound of the general formula (E)-IIA or (Z)-IIA, wherein X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; Y is a hydroxy group or an O - M + -group, where M + is a cation; and A 1 and A 2independently of one another, a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group. [11] Use according to claim 10, characterized by that for the preparation of a compound of general formula (E)-IIA or (Z)-IIA, in which X is a methyl group; Y is a hydroxy group; A 1 -(CH2)2-; and A 2 -(CH2)3-; one of the following compounds is used as a precursor: (E)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (Z)-2-Cyano-3-(2-methoxy-4-((3-((methylsulfonyl)oxy)propyl)(propyl)amino)-phenyl)acrylic acid; (E)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid; (Z)-2-Cyano-3-(2-methoxy-4-(propyl(3-(tosyloxy)propyl)amino)phenyl)acrylic acid. [12] Process for the preparation of a compound of general formula (E)-II or (Z)-IIwherein Y is a hydroxy group or an O - M + -group, where M + is a cation; Z 1 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group and a group -A 1 -X, where A 1is a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group, and X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; and Z 2 a remainder that [ 18 F]fluoride, where Z 2 is selected from the group consisting of a substituted or unsubstituted C1-C 12 -alkyl group, a substituted or unsubstituted C2-C 12 -alkenyl group, a substituted or unsubstituted C2-C 12 -alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted alkylaryl group and a substituted or unsubstituted arylalkyl group; or Z 2 -[ 18F]F a group -A 2 -[ 18 F]F is, where A 2 is a hydrocarbon chain having one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom may be arranged in the hydrocarbon chain to form an ether group; wherein a compound of the general formula (E)-I or (Z)-I wherein AG is selected from the group consisting of a hydroxy, -NO2, chlorine, bromine, iodine, a diazonium ion, a diazonium salt, a trialkylammonium ion, a trialkylammonium salt, a dialkoxyarene, a sulfoxide, a boronic acid, a boronic acid ester, an organotin compound, an iodonium ion, an iodonium salt, an iodonium ylide and a sulfonate; and Y, Z 1 and Z 2 which are related to the general formula (E)-II or (Z)-II have the meanings given, in the presence of a [ 18F]-fluoride anion and a phase transfer catalyst to form a compound of the general formula (E)-II or (Z)-II. [13] Method according to claim 12, characterized by that for the preparation of a compound of the general formula (E)-IIA or (Z)-IIAwherein X is selected from the group consisting of a methyl group, a halogen and a hydroxy group; Y is a hydroxy group or an O - M + group, where M + is a cation; and A 1 and A 2 are each independently a hydrocarbon chain with one to four substituted or unsubstituted methylene groups, wherein at least one oxygen atom can be arranged in the hydrocarbon chain to form an ether group; a compound of the general formula (E)-IA or (Z)-IA wherein AG is selected from the group consisting of a sulfonate, a chlorine, bromine, iodine and an organotin compound, and X, Y, A 1 and A 2 which have the meanings given in connection with the general formula (E)-IIA or (Z)-IIA, in the presence of the [ 18 F]-fluoride anion and the phase transfer catalyst to form a compound of the general formula (E)-IIA or (Z)-IIA. [14] Method according to claim 12 or claim 13, characterized by that the procedure is a one-step procedure. [15] Method according to one of claims 12 to 14, characterized by that the radical Y of the compound of the general formula (E)-I or (Z)-I does not have a protecting group during the reaction.

Citation Information

Patent Citations

  • Imaging ligands

    US20110217234A1

  • Therapeutic compounds

    WO2013109972A2

  • 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups

    WO2015004029A1